CVS girds for battle over cholesterol drugs

Drug retail giant CVS Health Corp. is girding to do battle with pharmaceutical companies over a coming class of cholesterol drugs that CVS says could cost the nation’s health-care system $150 billion a year.

CVS CVS, +0.20%  , the nation’s biggest health-related company with nearly $140 billion in annual sales , says this new strata of cholesterol drugs, believed to be a cut above previous medications, would severely strain the health-care system if prescribed to all the 15 million Americans who could benefit from the drugs.

Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.